CDSCO Panel approves Biological E's Phase IV clinical trial protocol to study PNEUBEVAX-14
Written By : Dr. Divya Colin
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-10-27 12:00 GMT | Update On 2024-10-27 12:00 GMT
Advertisement
New Delhi: The vaccine major Biological E has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of the Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)(14-valent) [PCV-14].
This came after Biological E presented the amended Phase IV clinical trial protocol titled “A prospective multicentre Phase-IV study to evaluate the safety of Biological E’s 14-valent Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX-14) when administered in 6-10-14 weeks dosing schedule to 6-8 week old healthy Indian infants.”
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.